Owens & Minor reported a slight increase in revenue to $2.632 billion for Q1 2025, up from $2.613 billion in Q1 2024. The company experienced a net loss of $24.982 million, or $0.32 per common share, but reported adjusted net income of $18.073 million, or $0.23 per share. The Patient Direct segment showed strong performance with mid-single digit top-line growth and mid-teen expansion in EBITDA.
Revenue for Q1 2025 was $2.632 billion, a slight increase from the previous year.
Patient Direct segment led top-line growth and expanded its operating margin by 173 basis points.
Adjusted EBITDA for the quarter was $121.9 million, up from $116.3 million in the prior year.
The company reaffirmed its 2025 financial guidance and remains engaged in the potential sale of its Products & Healthcare Services segment.
Owens & Minor reaffirmed its financial guidance for 2025, projecting revenue between $10.85 billion and $11.15 billion, adjusted EBITDA between $560 million and $590 million, and adjusted EPS between $1.60 and $1.85.